Skip to main navigation Skip to search Skip to main content

Bronchodilator reversibility testing in morbidly obese non-smokers: a comparative study– few concerns

  • Divya Balan*
  • , Manish R. Shetty
  • , Manu K. Mohan
  • *Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

Abstract

This is a letter in response to an article by Ahmed et al., which concluded that in comparison to salbutamol, Fluticasone/salmeterol combination increases FEV1, FEV1% of predicted, and FEV1/FVC ratio, however it did not offer novel insights, as both agents met the 12%- and 200-mL reversibility benchmarks and Concerns about incorporating a combination medication that includes an inhaled corticosteroid, inhaled corticosteroids are not typically associated with bronchodilation.

Original languageEnglish
Article number132
JournalBMC Pulmonary Medicine
Volume24
Issue number1
DOIs
Publication statusPublished - 12-2024

All Science Journal Classification (ASJC) codes

  • Pulmonary and Respiratory Medicine

Fingerprint

Dive into the research topics of 'Bronchodilator reversibility testing in morbidly obese non-smokers: a comparative study– few concerns'. Together they form a unique fingerprint.

Cite this